Insider Buying: Dr. Martens (LON:DOCS) Insider Purchases 202 Shares of Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 202 shares of Dr. Martens stock in a transaction on Thursday, June 11th. The shares were acquired at an average cost of GBX 74 per share, for a total transaction of £149.48.

Ije Nwokori also recently made the following trade(s):

• On Friday, June 12th, Ije Nwokori purchased 112,500 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 76 per share, with a total value of £85,500.
• On Wednesday, May 13th, Ije Nwokori purchased 233 shares of Dr. Martens stock. The shares were acquired at an average cost of GBX 64 per share, with a total value of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori acquired 232 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Trading Up 0.6%

LON DOCS traded up GBX 0.40 on Tuesday, reaching GBX 72.50. The company had a trading volume of 377,685 shares, compared to its average volume of 8,721,683. The firm has a market cap of £693.89 million, a price-to-earnings ratio of 30.21, a P/E/G ratio of 6.40 and a beta of 0.25. The company has a debt-to-equity ratio of 108.27, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens plc has a fifty-two week low of GBX 59.15 and a fifty-two week high of GBX 100.87. The business has a 50 day moving average of GBX 67.35 and a two-hundred day moving average of GBX 69.69.

Dr. Martens (LON:DOCS) last announced its earnings results on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The firm had revenue of £764.90 million for the quarter. Analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Berenberg Bank cut their price objective on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 100 target price on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Dr. Martens currently has an average rating of “Moderate Buy” and a consensus target price of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.